ACS
HUMA icon

Archford Capital Strategies’s Humacyte HUMA Stock Holding History

Archford Capital Strategies’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,500
Closed -$10.1K – 361
2025
Q4 		$10.1K Sell
10,500
-4,000
-28% -$5.66K ﹤0.01% 334
2025
Q3 		$25.2K Sell
14,500
-5,500
-28% -$10.8K ﹤0.01% 324
2025
Q2 		$41.8K Buy
+20,000
New +$38.4K 0.01% 321

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AP
Antipodes Partners Royal Exchange, Australia $5.19B AUM 36.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Archford Capital Strategies's HUMA Position: Q1 2026 in Review

Archford Capital Strategies sold out of Humacyte (HUMA) in Q1 2026, closing a stake of 10,500 shares — an estimated $10.1K sold.

Archford Capital Strategies first reported a position in HUMA in Q2 2025 and held it in 3 quarters. The position peaked at $41.8K in Q2 2025. 158 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

  • Archford Capital Strategies reported no remaining Humacyte position as of Q1 2026 after selling out during the quarter.
  • Archford Capital Strategies sold 10,500 Humacyte shares in Q1 2026, an estimated $10.1K.
  • Archford Capital Strategies first reported a position in Humacyte in Q2 2025 and held it in 3 quarters.
  • Archford Capital Strategies's Humacyte position peaked at $41.8K in Q2 2025.
  • 158 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Archford Capital Strategies's 13F filing for Q1 2026, filed 15 Apr 2026.